sacituzumab govitecan
gilead sciences
['bcsm', 'neostar', 'tnbc', 'sacituzumab']
#asco20 discusses results from the phase 2 #neostar trial in patients with localized #tnbc 4 cycles of #sacituzumabgovitecan achieved a pcr rate of 30% in patients with stage 1-3 #tnbc
#lauraspring #bcsm 
Medonc at dpt of general medical oncology @UZleuven ????Knight to improve outcome of breast cancer pts ???? #TNBC #BCY #HereditaryCancerSyndromes